The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $18.10

Today's change-0.65 -3.47%
Updated September 26 3:25 PM EDT. Delayed by at least 15 minutes.
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $18.10

Today's change-0.65 -3.47%
Updated September 26 3:25 PM EDT. Delayed by at least 15 minutes.

Nektar Therapeutics crosses below 20-day moving average

Nektar Therapeutics is sharply lower today, dropping (U.S.)$0.65 or 3.47% to (U.S.)$18.10 and crossing below its 20-day moving average. Shares have lost 4.69% over the last five days, but have gained 7.42% over the last year to date. This security has outperformed the S&P 500 by 40.24% during the last year.

Key company metrics

  • Open(U.S.) $18.56
  • Previous close(U.S.) $18.75
  • High(U.S.) $18.90
  • Low(U.S.) $18.02
  • Bid / Ask(U.S.) $18.09 / (U.S.) $18.10
  • YTD % change+7.42%
  • Volume1,290,424
  • Average volume (10-day)1,212,309
  • Average volume (1-month)1,044,269
  • Average volume (3-month)1,012,119
  • 52-week range(U.S.) $9.92 to (U.S.) $19.98
  • Beta1.63
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.97
Updated September 26 3:25 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue33593960
Total other revenue--------
Total revenue33593960
Gross profit25503153
Total cost of revenue8987
Total operating expense71688360
Selling / general / administrative11101310
Research & development52494743
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----14--
Other operating expenses, total--------
Operating income-38-9-430
Interest income (expense), net non-operating-11-11-11-9
Gain (loss) on sale of assets--------
Other--------
Income before tax-48-19-54-8
Income after tax-49-19-54-8
Income tax, total0000
Net income-49-19-54-8
Total adjustments to net income--------
Net income before extra. items-49-19-54-8
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-49-19-54-8
Inc. avail. to common incl. extra. items-49-19-54-8
Diluted net income-49-19-54-8
Dilution adjustment--0----
Diluted weighted average shares136136134133
Diluted EPS excluding extraordinary itemsvalue per share-0.36-0.14-0.40-0.06
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.36-0.14-0.34-0.06